• Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol

• Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.

• Written informed assent obtained from the subjects when applicable according to local requirements.

• A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)

• Body weight ≥ 6 kg/13.23 pounds.

• A subject is eligible if they meet at least one of the following criteria:

‣ Documented previous VZV vaccination OR

⁃ Medically verified varicella (with source documentation) OR

⁃ Seropositive for VZV prior to transplantation.

• Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1)

• Subject who has received an ABO compatible allogeneic renal transplant (allograft).

• Subject with stable renal function with stability defined as \<20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements.

• Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1).

• Female subjects of childbearing potential may be enrolled in the study, if the subject

‣ has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series